Navigation Links
Verenium Reports Financial Results For The First Quarter Ended March 31, 2013
Date:5/9/2013

Officer at Verenium. "As we have indicated in the past, we expect to make continued investments in our Product Pipeline as we prepare to launch new products in 2013, which should position us well for future growth."

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates (including, in each case, their value, potential for revenue growth and expected near-term and longer term revenue)and product pipeline (including the timing for commercial launch of any product candidates), lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance (including all financial guidance), and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, an
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Verenium Reports Financial Results For The Third Quarter And Nine Months Ended September 30, 2012
2. Verenium To Present At Upcoming Conferences
3. Verenium To Present At The Jefferies 2012 Global Industrial And Aerospace & Defense Conference
4. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
5. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
6. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
8. Chindex International, Inc. Reports First Quarter 2013 Financial Results
9. BioScrip Reports First Quarter 2013 Financial Results
10. China Biologic Reports Financial Results for the First Quarter of 2013
11. Nephros Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... pain clinic as a testing ground, researchers at Johns ... by Toyota in Japan can substantially reduce patient wait ... residents. , In a report on the pilot study, ... the researchers adopted the so-called "Just-in-Time" training and inventory ... to stem waste and keep complicated operations from bottlenecking. ...
(Date:9/16/2014)... Va. (PRWEB) September 16, 2014 ... through predictive analytics and targeted clinical programs, today ... announced changes support the Company’s drive to improve ... and targeted clinical programs. On September 2, 2014, ... company, Millennium Health, announced that RxAnte founder and ...
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... early-stage lung cancer who receive stereotactic body radiation ... 40 percent, according to research presented today at ... Annual Meeting. Such a positive survival rate is ... poor tumor control for patients with inoperable lung ... 0236, originally published in 2010 , and also ...
(Date:9/16/2014)... West Orange, NJ. September 16, 2014. Kessler Foundation ... of slowed processing speed in the executive deficits ... "Does slowed processing speed account for executive deficits ... structural neuroimaging," was published online ahead of print ... The authors are Victoria Leavitt, PhD, ...
Breaking Medicine News(10 mins):Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3
... ... in designing cutting-edge training facility for Kodak Dental Systems that features practice management ... ... August 4, 2009 -- Advanced Automation, a leader in comprehensive IT solutions and ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , ... (Pink Sheets: NXCO), developer of next generation digital media protection ... , a website that provides authors in the self-help/motivational market ... their downloadable materials. AmnestyQuest.com is a partnership between Nexicon and ...
... MINNEAPOLIS, Aug. 4 Court ordered Class Notice in Curtis, et al., ... , court File No. 27-CV-01-18042 (action filed 11/28/01). , , ... at any time before November 30, 2004, this class action notice may affect ... the marketing, advertising and promotion of Marlboro Lights cigarettes is pending in Hennepin ...
... , AVENTURA, Fla., Aug. 4 ... of highly specialized, nationally recognized orthopedic surgeons who have agreed ... business model of Centers of Excellence with Global Convenience(TM) ... orthopedic procedures domestically and abroad. The team represents a total ...
... ... has introduced a new technology offering including their new Scoreboard application. ... at a glance screen showing key business indicators updated in real-time. ... or both. The Scoreboard will be available to clients that either ...
Cached Medicine News:Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 2Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 3Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 3Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 4Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 5Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 2Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 3Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
... first time in the world, there is a ... to diagnose VVC in female patients. CanDia5® is ... detect the Candida antigens almost instantaneously (within 5 ... blood. There is no similar POC product for ...
... test for Candida albicans in only ... utilizes two enzyme color reactions to ... to read. AlbiQuicktm is performed on ... wells. Incubation time is only five ...
Medicine Products: